A Phase I, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects in Healthy Male and Female Japanese Subjects After Single and Multiple Doses (Bid) of AZD1722

Trial Profile

A Phase I, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects in Healthy Male and Female Japanese Subjects After Single and Multiple Doses (Bid) of AZD1722

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2014

At a glance

  • Drugs Tenapanor (Primary)
  • Indications Heart failure; Hyperphosphataemia; Irritable bowel syndrome; Kidney disorders
  • Focus Adverse reactions
  • Sponsors Ardelyx
  • Most Recent Events

    • 23 Oct 2014 Results presented at American Society of Nephrology (ASN) Kidney Week 2014, according to an Ardelyx media release.
    • 02 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top